OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. increased its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 28.1% during the third quarter, HoldingsChannel.com reports. The fund owned 66,060 shares of the medical instruments supplier’s stock after buying an additional 14,480 shares during the period. Principal Financial Group Inc.’s holdings in OraSure Technologies were worth $282,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Franklin Resources Inc. increased its position in OraSure Technologies by 28.5% in the 3rd quarter. Franklin Resources Inc. now owns 269,269 shares of the medical instruments supplier’s stock worth $1,091,000 after purchasing an additional 59,723 shares during the last quarter. Barclays PLC boosted its position in shares of OraSure Technologies by 182.6% in the third quarter. Barclays PLC now owns 195,793 shares of the medical instruments supplier’s stock valued at $836,000 after acquiring an additional 126,503 shares during the period. Geode Capital Management LLC increased its holdings in shares of OraSure Technologies by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,797,814 shares of the medical instruments supplier’s stock worth $7,678,000 after purchasing an additional 32,929 shares during the period. Jane Street Group LLC lifted its position in shares of OraSure Technologies by 6.4% in the 3rd quarter. Jane Street Group LLC now owns 296,194 shares of the medical instruments supplier’s stock worth $1,265,000 after acquiring an additional 17,758 shares during the period. Finally, Virtus Investment Advisers Inc. bought a new stake in OraSure Technologies in the 3rd quarter valued at $392,000. Institutional investors and hedge funds own 93.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a report on Wednesday, January 1st.

OraSure Technologies Price Performance

NASDAQ:OSUR opened at $3.74 on Tuesday. OraSure Technologies, Inc. has a fifty-two week low of $3.52 and a fifty-two week high of $8.33. The business’s 50-day simple moving average is $3.90 and its 200-day simple moving average is $4.13. The stock has a market capitalization of $278.98 million, a PE ratio of 24.93 and a beta of 0.05.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $39.92 million for the quarter, compared to analyst estimates of $38.97 million. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The business’s quarterly revenue was down 55.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.27 EPS. On average, research analysts expect that OraSure Technologies, Inc. will post -0.08 earnings per share for the current year.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.